Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TELA Bio, Inc. (TELA)
USD0.79
+0.04 (+4.68%)
US NASDAQ Healthcare Medical - Devices
Address
1 Great Valley Parkway 19355
Malvern, PA, US
Malvern, PA, US
CEO
Antony Koblish
Website
telabio.com
IPO
2019-11-07
CIK 1561921 ISIN US8723811084
Description
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.79
+0.04 (+4.68%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
177.1K
Beta
1.31
Float Shares
32.55M
Free Float %
72.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.88% | -15.04% | +71.34% | +21.66% | -13.51% | -18.64% | -2.04% | -89.87% | -91.79% | -92.81% | -92.81% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
0.79
Low
1.25
+59.1%
Consensus
2.42
+208.0%
Median
3.00
+281.9%
High
3.00
+281.9%
DCF (Unlevered)
1.20
+52.5%
DCF (Levered)
2.93
+272.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 3 |
2.42
+208.0%
|
| All Time | 9 |
9.14
+1,063.4%
|
Quality scores
Altman Z-Score
-7.47
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+15.8% ★ Q1'26: +2.9% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+37.6% ★ Q1'26: +16.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-47.0% Q1'26: -59.2% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-42.1% Q1'26: -55.2% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-303.5% Q1'26: -378.5% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+64.6% Q1'26: +26.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.65× Q1'26: -1.33× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
15.45M
est: 14.78M (+4.5%)
|
18.21M
est: 18.33M (-0.6%)
|
29.46M
est: 29.04M (+1.5%)
|
41.42M
est: 43.00M (-3.7%)
|
58.45M
est: 64.74M (-9.7%)
|
69.30M
est: 74.71M (-7.2%)
|
80.28M
est: 80.44M (-0.2%)
|
86.81M
86.20M – 87.49M
+7.9% YoY
|
96.78M
96.10M – 97.54M
+11.5% YoY
|
109.22M
108.60M – 109.83M
+12.9% YoY
|
| EBITDA |
-18.23M
est: -12.07M (-51.0%)
|
-24.71M
est: -14.98M (-65.0%)
|
-29.14M
est: -23.72M (-22.8%)
|
-39.06M
est: -35.13M (-11.2%)
|
-40.63M
est: 7.87M (-616.4%)
|
-31.68M
est: 9.08M (-448.9%)
|
-33.76M
est: 9.78M (-445.3%)
|
10.55M
10.48M – 10.63M
+7.9% YoY
|
11.76M
11.68M – 11.85M
+11.5% YoY
|
13.27M
13.20M – 13.35M
+12.9% YoY
|
| EBIT |
-18.82M
est: -12.27M (-53.3%)
|
-25.23M
est: -15.22M (-65.7%)
|
-29.68M
est: -24.12M (-23.1%)
|
-40.25M
est: -35.71M (-12.7%)
|
-41.44M
est: 8.51M (-586.7%)
|
-32.70M
est: 9.83M (-432.7%)
|
-33.76M
est: 10.58M (-419.1%)
|
11.42M
11.34M – 11.51M
+7.9% YoY
|
12.73M
12.64M – 12.83M
+11.5% YoY
|
14.36M
14.28M – 14.44M
+12.9% YoY
|
| Net Income |
-22.43M
est: -66.84M (+66.5%)
|
-28.79M
est: -60.97M (+52.8%)
|
-33.28M
est: -62.08M (+46.4%)
|
-44.30M
est: -77.84M (+43.1%)
|
-46.66M
est: -80.51M (+42.0%)
|
-37.84M
est: -64.52M (+41.4%)
|
-38.83M
est: -38.43M (-1.1%)
|
-31.93M
-32.24M – -31.62M
+16.9% YoY
|
-25.82M
-26.07M – -25.57M
+19.1% YoY
|
-21.76M
-21.97M – -21.55M
+15.7% YoY
|
| SGA |
24.28M
est: 20.63M (+17.7%)
|
32.25M
est: 25.59M (+26.0%)
|
41.52M
est: 40.54M (+2.4%)
|
57.11M
est: 60.03M (-4.9%)
|
74.57M
est: 80.18M (-7.0%)
|
79.37M
est: 92.52M (-14.2%)
|
78.88M
est: 99.61M (-20.8%)
|
107.50M
106.75M – 108.35M
+7.9% YoY
|
119.85M
119.01M – 120.79M
+11.5% YoY
|
135.25M
134.49M – 136.01M
+12.9% YoY
|
| EPS |
-2.26
est: -2.34 (+3.6%)
|
-2.23
est: -2.14 (-4.3%)
|
-2.30
est: -2.18 (-5.7%)
|
-2.73
est: -2.73 (0.0%)
|
-2.04
est: -1.71 (-19.0%)
|
-1.33
est: -1.37 (+3.2%)
|
-0.83
est: -0.82 (-1.5%)
|
-0.68
-0.69 – -0.67
+16.9% YoY
|
-0.55
-0.56 – -0.54
+19.1% YoY
|
-0.46
-0.47 – -0.46
+15.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-28.07M
OE per share TTM
-0.61
Owner's Yield
-55.98%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
5.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
42
Total invested
32.50M
Insider transactions (90d)
0
Beneficial owners (>5%)
32
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2-UGP, | 4.11M | 16.79% | 4.11M | — | 4.11M | — | CO | — | 2024-02-14 | ↗ |
| 2 | Martin P. Sutter | 4.11M | 16.79% | — | 4.11M | — | 4.11M | IN | — | 2024-02-14 | ↗ |
| 3 | Petri Vainio | 4.11M | 16.79% | — | 4.11M | — | 4.11M | IN | — | 2024-02-14 | ↗ |
| 4 | R. Scott Barry | 4.11M | 16.79% | — | 4.11M | — | 4.11M | IN | — | 2024-02-14 | ↗ |
| 5 | Ronald Eastman | 4.11M | 16.79% | — | 4.11M | — | 4.11M | IN | — | 2024-02-14 | ↗ |
| 6 | OrbiMed Advisors LLC | 3.06M | 21.20% | — | 3.06M | — | 10.00 | IA | Delaware | 2020-07-01 | ↗ |
| 7 | OrbiMed Capital GP IV LLC | 3.06M | 21.20% | — | 3.06M | — | 10.00 | OO | Delaware | 2020-07-01 | ↗ |
| 8 | Jon M. Plexico | 2.83M | 11.00% | — | 2.83M | — | 2.83M | HC, IN | Delaware | 2024-10-29 | ↗ |
| 9 | Stonepine Capital Management, LLC | 2.83M | 11.00% | — | 2.83M | — | 2.83M | IA, OO | Delaware | 2024-10-29 | ↗ |
| 10 | Stonepine Capital, L.P. | 2.83M | 11.00% | — | 2.83M | — | 2.83M | PN | Delaware | 2024-10-29 | ↗ |
| 11 | Stonepine GP, LLC | 2.83M | 11.00% | — | 2.83M | — | 2.83M | OO | Delaware | 2024-10-29 | ↗ |
| 12 | Mathew P. Arens | 2.72M | 11.12% | 30.0K | 2.69M | 30.0K | 2.69M | IN | Delaware | 2024-02-14 | ↗ |
| 13 | First Light Asset Management, LLC | 2.56M | 10.47% | — | 2.56M | — | 2.56M | IA | Delaware | 2024-02-14 | ↗ |
| 14 | 2-A, | 2.50M | 10.19% | 2.50M | — | 2.50M | — | PN | — | 2024-02-14 | ↗ |
| 15 | Quaker BioVentures Capital II, L.P | 1.77M | 15.50% | — | 1.77M | — | — | PN | Delaware | 2020-02-14 | ↗ |
| 16 | L.P. | 1.62M | 6.60% | 1.62M | — | 1.62M | — | PN | — | 2024-02-14 | ↗ |
| 17 | 27-4413262 | 1.52M | 7.90% | 1.52M | — | — | — | OO | Maryland | 2022-08-24 | ↗ |
| 18 | Identification Nos. of above persons (. | 1.52M | 7.90% | 1.52M | — | 1.52M | — | IN | States | 2022-08-24 | ↗ |
| 19 | RTW Investments, LP | 1.38M | 9.59% | — | 1.38M | — | 1.38M | IA, PN, OO | Delaware | 2021-02-12 | ↗ |
| 20 | Roderick Wong | 1.38M | 9.59% | — | 1.38M | — | 1.38M | HC, IN | Delaware | 2021-02-12 | ↗ |
| 21 | Laurence W. Lytton | 1.34M | 11.00% | 1.34M | 400.00 | 1.34M | 400.00 | IN | USA | 2024-07-22 | ↗ |
| 22 | RTW Master Fund, Ltd. | 988.9K | 6.85% | — | 988.9K | — | 988.9K | CO | Delaware | 2021-02-12 | ↗ |
| 23 | 2 | 769.2K | 6.99% | 312.8K | — | 312.8K | — | IN | Delaware | 2019-11-27 | ↗ |
| 24 | Efrem Kamen | 757.5K | 5.25% | — | — | — | 757.5K | HC, IN | Delaware | 2021-06-21 | ↗ |
| 25 | Pura Vida Investments, LLC | 757.5K | 5.25% | — | — | — | 757.5K | IA | Delaware | 2021-06-21 | ↗ |
| 26 | James C. Gale | 618.6K | 5.42% | — | 618.6K | — | — | IN | Delaware | 2020-07-15 | ↗ |
| 27 | Signet Healthcare GP III, LP | 618.6K | 5.42% | — | 618.6K | — | — | OO | Delaware | 2020-07-15 | ↗ |
| 28 | Signet Healthcare Management LLC | 618.6K | 5.42% | — | 618.6K | — | — | IA | Delaware | 2020-07-15 | ↗ |
| 29 | Signet Holdings, LLC | 618.6K | 5.42% | — | 618.6K | — | — | OO | Delaware | 2020-07-15 | ↗ |
| 30 | Signet Healthcare Partners QP Partnership III, LP | 511.3K | 4.48% | — | 511.3K | — | — | PN | Delaware | 2020-07-15 | ↗ |
| 31 | Signet Healthcare Partners Accredited Partnership III, LP | 107.3K | 0.98% | — | 107.3K | — | — | PN | Delaware | 2020-07-15 | ↗ |
| 32 | Quaker BioVentures II, L.P. | 18.1K | 0.12% | — | 18.1K | — | 18.1K | PN | Delaware | 2022-06-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
42
+0 vs prev Q
New positions
7
Closed positions
7
Increased
19
Reduced
7
Put/Call ratio
0.00
Calls held
750.0K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ESSEX WOODLANDS MANAGEMENT, INC. | 7.71M +3.6M (+87.7%) | 9.10M +3.0M (+48.6%) | 16.98% +7.923 pp | 2.86% +0.866 pp | USD6.59 -82.1% | 25 qtrs — |
| 2 | SILVERARC CAPITAL MANAGEMENT, LLC | 2.65M -135.4K (-4.9%) | 3.12M -1.0M (-24.7%) | 5.83% -0.306 pp | 0.43% -0.125 pp | USD4.52 -73.9% | 12 qtrs — |
| 3 | STONEPINE CAPITAL MANAGEMENT, LLC | 2.35M +196.5K (+9.1%) | 2.78M -436.3K (-13.6%) | 5.18% +0.427 pp | 2.03% -0.585 pp | USD3.77 -68.7% | 11 qtrs — |
| 4 | VANGUARD GROUP INC | 1.83M +30.7K (+1.7%) | 2.16M -521.8K (-19.5%) | 4.03% +0.063 pp | 0.00% +0.000 pp | USD6.96 -83.0% | 25 qtrs — |
| 5 | UBS GROUP AG | 1.50M +1.3M (+592.1%) | 1.77M +1.4M (+448.1%) | 3.30% +2.826 pp | 0.00% +0.000 pp | USD1.45 -18.6% | 25 qtrs — |
| 6 | DAFNA CAPITAL MANAGEMENT LLC | 1.44M +— (+0.0%) | 1.70M -446.7K (-20.8%) | 3.17% -0.004 pp | 0.40% -0.136 pp | USD3.02 -60.9% | 5 qtrs — |
| 7 | PERKINS CAPITAL MANAGEMENT INC | 1.40M +563.5K (+67.6%) | 1.65M +406.4K (+32.7%) | 3.08% +1.238 pp | 1.31% +0.214 pp | USD3.01 -60.8% | 14 qtrs — |
| 8 | CITIGROUP INC | 750.0K +— (+0.0%) | 885.0K -232.5K (-20.8%) | 1.65% -0.002 pp | 0.00% 0.000 pp | USD2.54 -53.5% | 13 qtrs — |
| 9 | NANTAHALA CAPITAL MANAGEMENT, LLC | 750.0K +— (+0.0%) | 885.0K -232.5K (-20.8%) | 1.65% -0.002 pp | 0.03% -0.010 pp | USD2.53 -53.4% | 6 qtrs — |
| 10 | SIO CAPITAL MANAGEMENT, LLC | 636.3K +— (+0.0%) | 750.8K -197.3K (-20.8%) | 1.40% -0.002 pp | 0.12% -0.122 pp | USD3.01 -60.8% | 5 qtrs — |
| 11 | BLACKROCK, INC. | 462.4K +1.7K (+0.4%) | 545.6K -140.7K (-20.5%) | 1.02% +0.003 pp | 0.00% +0.000 pp | USD2.48 -52.4% | 6 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 361.5K +4.8K (+1.3%) | 426.6K -105.0K (-19.7%) | 0.80% +0.010 pp | 0.00% +0.000 pp | USD6.31 -81.3% | 25 qtrs — |
| 13 | WEALTHTRUST AXIOM LLC | 322.6K +90.7K (+39.1%) | 380.7K +35.1K (+10.1%) | 0.71% +0.199 pp | 0.10% +0.005 pp | USD1.43 -17.5% | 3 qtrs — |
| 14 | NORTHERN TRUST CORP | 174.4K -921.0 (-0.5%) | 205.8K -55.4K (-21.2%) | 0.38% -0.003 pp | 0.00% +0.000 pp | USD3.33 -64.6% | 25 qtrs — |
| 15 | RENAISSANCE TECHNOLOGIES LLC | 128.7K +64.8K (+101.4%) | 151.9K +56.7K (+59.5%) | 0.28% +0.143 pp | 0.00% +0.000 pp | USD2.19 -46.1% | 20 qtrs — |
| 16 | EMBREE FINANCIAL GROUP | 111.3K +97.3K (+695.1%) | 131.4K +110.5K (+529.7%) | 0.25% +0.214 pp | 0.02% +0.013 pp | USD1.34 -11.9% | 6 qtrs — |
| 17 | GSA CAPITAL PARTNERS LLP | 73.8K -32.0K (-30.2%) | 87.0K -71.0K (-44.9%) | 0.16% -0.071 pp | 0.01% -0.006 pp | USD2.15 -45.1% | 8 qtrs — |
| 18 | UP STRATEGIC WEALTH INVESTMENT ADVISORS LLC | 99.9K +— (+0.0%) | 81.0K -66.8K (-45.2%) | 0.22% 0.000 pp | 0.06% -0.052 pp | USD3.42 -65.5% | 9 qtrs — |
| 19 | STATE STREET CORP | 63.4K +— (+0.0%) | 74.8K -19.6K (-20.8%) | 0.14% 0.000 pp | 0.00% +0.000 pp | USD9.30 -87.3% | 23 qtrs — |
| 20 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 57.5K +— (+0.0%) | 67.9K -17.8K (-20.8%) | 0.13% 0.000 pp | 0.00% 0.000 pp | USD5.64 -79.1% | 20 qtrs — |
| 21 | PNC FINANCIAL SERVICES GROUP, INC. | 53.6K +— (+0.0%) | 63.3K -16.6K (-20.8%) | 0.12% 0.000 pp | 0.00% +0.000 pp | USD12.23 -90.4% | 23 qtrs — |
| 22 | DESTINY WEALTH PARTNERS, LLC | 52.5K +— (+0.0%) | 50.7K -27.5K (-35.2%) | 0.12% 0.000 pp | 0.01% -0.004 pp | USD1.94 -39.2% | 3 qtrs — |
| 23 | XTX TOPCO LTD | 41.0K +41.0K (+100.0%) | 48.3K +48.3K (+100.0%) | 0.09% +0.090 pp | 0.00% +0.001 pp | USD1.18 +0.0% | 1 qtrs NEW |
| 24 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 37.2K -48.6K (-56.7%) | 43.9K -83.9K (-65.7%) | 0.08% -0.107 pp | 0.00% +0.000 pp | USD1.45 -18.6% | 9 qtrs — |
| 25 | RAYMOND JAMES FINANCIAL INC | 30.2K +10.0K (+49.5%) | 35.6K +5.5K (+18.4%) | 0.07% +0.022 pp | 0.00% +0.000 pp | USD1.54 -23.4% | 3 qtrs — |
| 26 | CITADEL ADVISORS LLC | 23.4K -11.9K (-33.7%) | 27.6K -25.0K (-47.5%) | 0.05% -0.026 pp | 0.00% +0.000 pp | USD1.49 -20.8% | 13 qtrs — |
| 27 | ACADIAN ASSET MANAGEMENT LLC | 20.8K +20.8K (+100.0%) | 24.0K +24.0K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.000 pp | USD1.18 +0.0% | 1 qtrs NEW |
| 28 | — | 20.0K +20.0K (+100.0%) | 23.6K +23.6K (+100.0%) | 0.04% +0.044 pp | 0.01% +0.009 pp | USD1.18 +0.0% | 1 qtrs NEW |
| 29 | GREAT VALLEY ADVISOR GROUP, INC. | 19.6K +19.6K (+100.0%) | 23.1K +23.1K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.000 pp | USD1.18 +0.0% | 1 qtrs NEW |
| 30 | NINE MASTS CAPITAL LTD | 16.5K +16.5K (+100.0%) | 19.5K +19.5K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.003 pp | USD1.18 +0.0% | 1 qtrs NEW |
| 31 | VIRTU FINANCIAL LLC | 10.7K +10.7K (+100.0%) | 13.0K +13.0K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.001 pp | USD1.18 +0.0% | 3 qtrs — |
| 32 | HIGHTOWER ADVISORS, LLC | 10.4K +— (+0.0%) | 12.2K -3.2K (-20.8%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.48 -20.3% | 4 qtrs — |
| 33 | WELLS FARGO & COMPANY/MN | 4.2K +— (+0.0%) | 5.0K -1.3K (-20.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.94 -39.2% | 3 qtrs — |
| 34 | MORGAN STANLEY | 2.2K +— (+0.0%) | 2.6K -688.0 (-20.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.27 -48.0% | 13 qtrs — |
| 35 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 2.0K +— (+0.0%) | 2.3K -618.0 (-20.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.22 -3.3% | 4 qtrs — |
| 36 | SBI SECURITIES CO., LTD. | 301.00 -1.0 (-0.3%) | 355.00 -95.0 (-21.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.01 -60.8% | 5 qtrs — |
| 37 | BNP PARIBAS ARBITRAGE, SNC | 210.00 +— (+0.0%) | 248.00 -65.0 (-20.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.01 -60.8% | 5 qtrs — |
| 38 | ADVISOR GROUP HOLDINGS, INC. | 100.00 +— (+0.0%) | 118.00 -32.0 (-21.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.22 -3.3% | 4 qtrs — |
| 39 | JPMORGAN CHASE & CO | 39.00 -300.0 (-88.5%) | 46.00 -459.0 (-90.9%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD3.03 -61.1% | 14 qtrs — |
| 40 | BANK OF AMERICA CORP /DE/ | 36.00 +1.0 (+2.9%) | 42.00 -10.0 (-19.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.11 -80.7% | 13 qtrs — |
| 41 | SIMPLEX TRADING, LLC | 3.00 +3.0 (+100.0%) | 3.00 +3.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +18.0% | 1 qtrs NEW |
| 42 | CWM, LLC | — -337.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 43 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | — -747.4K (-100.0%) | — -1.1M (-100.0%) | 0.00% -1.648 pp | 0.00% -1.046 pp | USD— | 17 qtrs SOLD |
| 44 | HBK SORCE ADVISORY LLC | — -100.4K (-100.0%) | — -153.6K (-100.0%) | 0.00% -0.221 pp | 0.00% -0.004 pp | USD— | 2 qtrs SOLD |
| 45 | BIRCHVIEW CAPITAL, LP | — -155.0K (-100.0%) | — -231.0K (-100.0%) | 0.00% -0.342 pp | 0.00% -0.174 pp | USD— | 5 qtrs SOLD |
| 46 | PENTWATER CAPITAL MANAGEMENT LP | — -724.9K (-100.0%) | — -1.1M (-100.0%) | 0.00% -1.598 pp | 0.00% -0.006 pp | USD— | 25 qtrs SOLD |
| 47 | PARADIGM CAPITAL MANAGEMENT INC/NY | — -200.0K (-100.0%) | — -298.0K (-100.0%) | 0.00% -0.441 pp | 0.00% -0.013 pp | USD— | 4 qtrs SOLD |
| 48 | ROYAL BANK OF CANADA | — -603.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 369.3K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 2.4K | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 6.5K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 479.31 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.11M | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.4K | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.3K | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 534.32 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 58.89 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 8.28 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.92
Neutral
Ratio by volume
3.00
Bullish
Buys
11
Sells
12
Shares acquired
1.06M
Shares disposed
53.8K
Cash buys
—
Cash sales
—
Net activity
+1,005,016
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-01 | Langstein Howard N. | Officer | — | — | Common Stock | 0 | 0.00 | — | 71,347 | D | ↗ |
| 2026-02-24 | KOBLISH ANTONY | Director / Officer | F-InKind | D | Common Stock | 3,900 | 0.79 | 3.1K | 586,210 | D | ↗ |
| 2026-02-23 | Talmo Paul | Officer | F-InKind | D | Common Stock | 4,061 | 0.77 | 3.1K | 173,436 | D | ↗ |
| 2026-02-23 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 423 | 0.77 | 324.02 | 66,873 | D | ↗ |
| 2026-02-23 | KOBLISH ANTONY | Director / Officer | F-InKind | D | Common Stock | 11,631 | 0.77 | 8.9K | 741,985 | D | ↗ |
| 2026-02-23 | Firestone Gregory A. | Officer | F-InKind | D | Common Stock | 1,352 | 0.77 | 1.0K | 139,307 | D | ↗ |
| 2026-02-23 | Cuca Roberto | Officer | F-InKind | D | Common Stock | 5,234 | 0.77 | 4.0K | 257,377 | D | ↗ |
| 2026-02-21 | Talmo Paul | Officer | F-InKind | D | Common Stock | 3,385 | 0.72 | 2.4K | 177,497 | D | ↗ |
| 2026-02-21 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 1,590 | 0.72 | 1.1K | 67,296 | D | ↗ |
| 2026-02-21 | KOBLISH ANTONY | Director / Officer | F-InKind | D | Common Stock | 12,494 | 0.72 | 9.0K | 753,616 | D | ↗ |
| 2026-02-21 | Firestone Gregory A. | Officer | F-InKind | D | Common Stock | 4,189 | 0.72 | 3.0K | 140,659 | D | ↗ |
| 2026-02-21 | Cuca Roberto | Officer | F-InKind | D | Common Stock | 4,780 | 0.72 | 3.4K | 262,611 | D | ↗ |
| 2026-02-20 | Talmo Paul | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 0.72 | 60.9K | 85,000 | D | ↗ |
| 2026-02-20 | KOBLISH ANTONY | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 261,000 | 0.72 | 187.1K | 261,000 | D | ↗ |
| 2026-02-20 | Firestone Gregory A. | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 0.72 | 39.4K | 55,000 | D | ↗ |
| 2026-02-20 | Cuca Roberto | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 0.72 | 60.9K | 85,000 | D | ↗ |
| 2026-02-20 | Blizard Jeffrey | Officer | A-Award | A | Stock Option (Right to Buy) | 127,000 | 0.72 | 91.1K | 127,000 | D | ↗ |
| 2026-02-19 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 795 | 0.80 | 632.03 | 68,886 | D | ↗ |
| 2026-02-18 | Smeykal Megan | Officer | A-Award | A | Common Stock | 32,850 | 0.00 | — | 69,681 | D | ↗ |
| 2025-11-17 | EW HEALTHCARE PARTNERS FUND 2, L.P. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 3,604,000 | 1.11 | 4.00M | 7,714,709 | D | ↗ |
| 2025-10-31 | Plovanic William J. | Director | A-Award | A | Stock Option (Right to Buy) | 17,550 | 1.23 | 21.6K | 17,550 | D | ↗ |
| 2025-10-09 | Rocchio Betty Jo | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-03 | Firestone Gregory A. | Officer | F-InKind | D | Common Stock | 1,093 | 1.86 | 2.0K | 106,790 | D | ↗ |
| 2025-06-02 | Blizard Jeffrey | Officer | A-Award | A | Stock Option (Right to Buy) | 154,100 | 1.42 | 218.8K | 154,100 | D | ↗ |
| 2025-05-28 | O'Brien Federica F. | Director | A-Award | A | Stock Option (Right to Buy) | 11,700 | 1.39 | 16.3K | 11,700 | D | ↗ |
| 2025-05-28 | EVANS DOUGLAS G | Director | A-Award | A | Stock Option (Right to Buy) | 11,700 | 1.39 | 16.3K | 11,700 | D | ↗ |
| 2025-05-28 | COLLERAN LISA N | Director | A-Award | A | Stock Option (Right to Buy) | 11,700 | 1.39 | 16.3K | 11,700 | D | ↗ |
| 2025-05-28 | Burgess Vincent J | Director | A-Award | A | Stock Option (Right to Buy) | 11,700 | 1.39 | 16.3K | 11,700 | D | ↗ |
| 2025-05-28 | Blizard Jeffrey | Director | A-Award | A | Stock Option (Right to Buy) | 11,700 | 1.39 | 16.3K | 11,700 | D | ↗ |
| 2025-05-28 | Azarbarzin Kurt | Director | A-Award | A | Stock Option (Right to Buy) | 11,700 | 1.39 | 16.3K | 11,700 | D | ↗ |
| 2025-03-31 | Talmo Paul | Officer | F-InKind | D | Common Stock | 190 | 1.22 | 231.80 | 123,882 | D | ↗ |
| 2025-03-31 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 96 | 1.22 | 117.12 | 36,831 | D | ↗ |
| 2025-03-31 | KOBLISH ANTONY | Director / Officer | F-InKind | D | Common Stock | 384 | 1.22 | 468.48 | 590,110 | D | ↗ |
| 2025-03-31 | Firestone Gregory A. | Officer | F-InKind | D | Common Stock | 119 | 1.22 | 145.18 | 106,804 | D | ↗ |
| 2025-02-24 | Talmo Paul | Officer | F-InKind | D | Common Stock | 1,049 | 2.65 | 2.8K | 124,072 | D | ↗ |
| 2025-02-24 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 539 | 2.65 | 1.4K | 36,927 | D | ↗ |
| 2025-02-24 | KOBLISH ANTONY | Director / Officer | F-InKind | D | Common Stock | 5,772 | 2.65 | 15.3K | 590,494 | D | ↗ |
| 2025-02-24 | Firestone Gregory A. | Officer | F-InKind | D | Common Stock | 240 | 2.65 | 636.00 | 106,923 | D | ↗ |
| 2025-02-23 | Talmo Paul | Officer | F-InKind | D | Common Stock | 4,061 | 2.72 | 11.0K | 125,121 | D | ↗ |
| 2025-02-23 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 423 | 2.72 | 1.2K | 37,466 | D | ↗ |
| 2025-02-23 | KOBLISH ANTONY | Director / Officer | F-InKind | D | Common Stock | 11,631 | 2.72 | 31.6K | 596,266 | D | ↗ |
| 2025-02-23 | Firestone Gregory A. | Officer | F-InKind | D | Common Stock | 1,352 | 2.72 | 3.7K | 107,163 | D | ↗ |
| 2025-02-23 | Cuca Roberto | Officer | F-InKind | D | Common Stock | 5,234 | 2.72 | 14.2K | 208,233 | D | ↗ |
| 2025-02-21 | Talmo Paul | Officer | A-Award | A | Common Stock | 38,100 | 0.00 | — | 129,182 | D | ↗ |
| 2025-02-21 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 1,590 | 2.72 | 4.3K | 37,889 | D | ↗ |
| 2025-02-21 | KOBLISH ANTONY | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 219,000 | 2.72 | 595.7K | 219,000 | D | ↗ |
| 2025-02-21 | Firestone Gregory A. | Officer | F-InKind | D | Common Stock | 364 | 2.72 | 990.08 | 108,515 | D | ↗ |
| 2025-02-21 | Cuca Roberto | Officer | A-Award | A | Stock Option (Right to Buy) | 83,800 | 2.72 | 227.9K | 83,800 | D | ↗ |
| 2025-02-19 | Smeykal Megan | Officer | A-Award | A | Common Stock | 9,400 | 0.00 | — | 39,479 | D | ↗ |
| 2024-10-24 | Talmo Paul | Officer | P-Purchase | A | Common Stock | 22,222 | 2.25 | 50.0K | 91,082 | D | ↗ |
| 2024-10-24 | KOBLISH ANTONY | Director / Officer | P-Purchase | A | Common Stock | 88,888 | 2.25 | 200.0K | 458,897 | D | ↗ |
| 2024-10-24 | Firestone Gregory A. | Officer | P-Purchase | A | Common Stock | 6,666 | 2.25 | 15.0K | 57,279 | D | ↗ |
| 2024-10-24 | Cuca Roberto | Officer | P-Purchase | A | Common Stock | 64,444 | 2.25 | 145.0K | 155,388 | D | ↗ |
| 2024-08-03 | Firestone Gregory A. | Officer | F-InKind | D | Common Stock | 1,093 | 4.25 | 4.6K | 50,613 | — | ↗ |
| 2024-07-02 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 36,600 | 4.54 | 166.2K | 2,407,242 | — | ↗ |
| 2024-07-01 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 13,700 | 4.68 | 64.1K | 2,443,842 | — | ↗ |
| 2024-06-28 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 378,000 | 4.74 | 1.79M | 2,457,542 | — | ↗ |
| 2024-06-04 | O'Brien Federica F. | Director | A-Award | A | Stock Option (Right to Buy) | 6,200 | 5.71 | 35.4K | 6,200 | — | ↗ |
| 2024-06-04 | EVANS DOUGLAS G | Director | A-Award | A | Stock Option (Right to Buy) | 6,200 | 5.71 | 35.4K | 6,200 | — | ↗ |
| 2024-06-04 | COLLERAN LISA N | Director | A-Award | A | Stock Option (Right to Buy) | 6,200 | 5.71 | 35.4K | 6,200 | — | ↗ |
| 2024-06-04 | Burgess Vincent J | Director | A-Award | A | Common Stock | 4,250 | 0.00 | — | 15,380 | — | ↗ |
| 2024-06-04 | Blizard Jeffrey | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-04 | Azarbarzin Kurt | Director | A-Award | A | Common Stock | 4,250 | 0.00 | — | 10,520 | — | ↗ |
| 2024-03-31 | Talmo Paul | Officer | F-InKind | D | Common Stock | 190 | 5.67 | 1.1K | 68,860 | — | ↗ |
| 2024-03-31 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 96 | 5.67 | 544.32 | 29,000 | — | ↗ |
| 2024-03-31 | Murphy Peter C. | Officer | F-InKind | D | Common Stock | 163 | 5.67 | 924.21 | 48,129 | — | ↗ |
| 2024-03-31 | KOBLISH ANTONY | Director / Officer | F-InKind | D | Common Stock | 385 | 5.67 | 2.2K | 370,009 | — | ↗ |
| 2024-03-31 | Firestone Gregory A. | Officer | F-InKind | D | Common Stock | 119 | 5.67 | 674.73 | 50,627 | — | ↗ |
| 2024-02-24 | Talmo Paul | Officer | F-InKind | D | Common Stock | 1,049 | 7.07 | 7.4K | 69,050 | — | ↗ |
| 2024-02-24 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 539 | 7.07 | 3.8K | 29,096 | — | ↗ |
| 2024-02-24 | Murphy Peter C. | Officer | F-InKind | D | Common Stock | 940 | 7.07 | 6.6K | 48,292 | — | ↗ |
| 2024-02-24 | KOBLISH ANTONY | Director / Officer | F-InKind | D | Common Stock | 5,726 | 7.07 | 40.5K | 370,394 | — | ↗ |
| 2024-02-24 | Firestone Gregory A. | Officer | F-InKind | D | Common Stock | 240 | 7.07 | 1.7K | 50,746 | — | ↗ |
| 2024-02-23 | Talmo Paul | Officer | A-Award | A | Stock Option (Right to Buy) | 24,400 | 7.07 | 172.5K | 24,400 | — | ↗ |
| 2024-02-23 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 423 | 7.07 | 3.0K | 29,635 | — | ↗ |
| 2024-02-23 | Murphy Peter C. | Officer | A-Award | A | Common Stock | 13,200 | 0.00 | — | 51,547 | — | ↗ |
| 2024-02-23 | KOBLISH ANTONY | Director / Officer | F-InKind | D | Common Stock | 5,014 | 7.07 | 35.4K | 376,120 | — | ↗ |
| 2024-02-23 | Firestone Gregory A. | Officer | F-InKind | D | Common Stock | 240 | 7.07 | 1.7K | 50,986 | — | ↗ |
| 2024-02-23 | Cuca Roberto | Officer | A-Award | A | Stock Option (Right to Buy) | 42,700 | 7.07 | 301.9K | 42,700 | — | ↗ |
| 2024-02-21 | Smeykal Megan | Officer | A-Award | A | Common Stock | 9,400 | 0.00 | — | 30,058 | — | ↗ |
| 2024-02-21 | Firestone Gregory A. | Officer | F-InKind | D | Common Stock | 364 | 7.00 | 2.5K | 36,226 | — | ↗ |
| 2023-12-05 | Firestone Gregory A. | Officer | P-Purchase | A | Common Stock | 2,600 | 5.65 | 14.7K | 35,511 | — | ↗ |
| 2023-11-14 | KOBLISH ANTONY | Director / Officer | P-Purchase | A | Common Stock | 11,000 | 4.54 | 50.0K | 303,634 | — | ↗ |
| 2023-11-14 | Cuca Roberto | Officer | P-Purchase | A | Common Stock | 10,000 | 4.49 | 44.9K | 62,371 | — | ↗ |
| 2023-08-03 | Firestone Gregory A. | Officer | A-Award | A | Common Stock | 17,950 | 0.00 | — | 32,911 | — | ↗ |
| 2023-06-01 | O'Brien Federica F. | Director | A-Award | A | Common Stock | 3,135 | 0.00 | — | 6,270 | — | ↗ |
| 2023-06-01 | Nosenzo John | Director | A-Award | A | Stock Option (Right to Buy) | 5,360 | 10.34 | 55.4K | 5,360 | — | ↗ |
| 2023-06-01 | EVANS DOUGLAS G | Director | A-Award | A | Stock Option (Right to Buy) | 5,360 | 10.34 | 55.4K | 5,360 | — | ↗ |
| 2023-06-01 | COLLERAN LISA N | Director | A-Award | A | Common Stock | 3,135 | 0.00 | — | 6,270 | — | ↗ |
| 2023-06-01 | Burgess Vincent J | Director | A-Award | A | Stock Option (Right to Buy) | 5,360 | 10.34 | 55.4K | 5,360 | — | ↗ |
| 2023-06-01 | Azarbarzin Kurt | Director | A-Award | A | Stock Option (Right to Buy) | 5,360 | 10.34 | 55.4K | 5,360 | — | ↗ |
| 2023-04-21 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 27,700 | 9.41 | 260.7K | 2,835,542 | — | ↗ |
| 2023-04-20 | Opaleye Management Inc. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-04-20 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 28,300 | 9.43 | 266.9K | 2,863,242 | — | ↗ |
| 2023-04-19 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 136,000 | 9.30 | 1.26M | 2,891,542 | — | ↗ |
| 2023-03-31 | Talmo Paul | Officer | F-InKind | D | Common Stock | 187 | 10.64 | 2.0K | 55,976 | — | ↗ |
| 2023-03-31 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 96 | 10.64 | 1.0K | 20,431 | — | ↗ |
| 2023-03-31 | Murphy Peter C. | Officer | F-InKind | D | Common Stock | 163 | 10.64 | 1.7K | 37,987 | — | ↗ |
| 2023-03-31 | KOBLISH ANTONY | Director / Officer | F-InKind | D | Common Stock | 385 | 10.64 | 4.1K | 292,634 | — | ↗ |
| 2023-03-29 | Burgess Vincent J | Director | M-Exempt | A | Common Stock | 4,860 | 4.44 | 21.6K | 7,995 | — | ↗ |
| 2023-02-24 | Talmo Paul | Officer | F-InKind | D | Common Stock | 1,032 | 11.03 | 11.4K | 56,163 | — | ↗ |
| 2023-02-24 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 539 | 11.03 | 5.9K | 20,527 | — | ↗ |
| 2023-02-24 | Murphy Peter C. | Officer | F-InKind | D | Common Stock | 940 | 11.03 | 10.4K | 38,150 | — | ↗ |
| 2023-02-24 | KOBLISH ANTONY | Officer | F-InKind | D | Common Stock | 6,034 | 11.03 | 66.6K | 293,019 | — | ↗ |
| 2023-02-23 | Talmo Paul | Officer | A-Award | A | Common Stock | 16,800 | 0.00 | — | 58,262 | — | ↗ |
| 2023-02-23 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 423 | 10.50 | 4.4K | 21,066 | — | ↗ |
| 2023-02-23 | Murphy Peter C. | Officer | A-Award | A | Stock Option (Right to Buy) | 26,400 | 10.50 | 277.2K | 26,400 | — | ↗ |
| 2023-02-23 | KOBLISH ANTONY | Officer | A-Award | A | Stock Option (Right to Buy) | 96,100 | 10.50 | 1.01M | 96,100 | — | ↗ |
| 2023-02-23 | Cuca Roberto | Officer | A-Award | A | Stock Option (Right to Buy) | 27,700 | 10.50 | 290.9K | 27,700 | — | ↗ |
| 2023-02-21 | Smeykal Megan | Officer | A-Award | A | Common Stock | 9,400 | 0.00 | — | 21,489 | — | ↗ |
| 2022-11-03 | Opaleye Management Inc. | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 1,262 | 7.81 | 9.9K | 124,813 | — | ↗ |
| 2022-10-11 | Opaleye Management Inc. | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 15,000 | 8.00 | 120.0K | 1,929,000 | — | ↗ |
| 2022-09-23 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 6,500 | 7.99 | 52.0K | 1,914,000 | — | ↗ |
| 2022-09-19 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 17,000 | 8.09 | 137.5K | 1,907,500 | — | ↗ |
| 2022-09-16 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 372 | 8.08 | 3.0K | 121,247 | — | ↗ |
| 2022-09-15 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 658 | 8.10 | 5.3K | 120,875 | — | ↗ |
| 2022-08-17 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 500,000 | 8.00 | 4.00M | 4,105,709 | — | ↗ |
| 2022-08-16 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 8.10 | 40.5K | 1,885,000 | — | ↗ |
| 2022-08-10 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 479 | 8.52 | 4.1K | 105,000 | — | ↗ |
| 2022-08-01 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 4,500 | 7.96 | 35.8K | 1,568,500 | I | ↗ |
| 2022-07-22 | Opaleye Management Inc. | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 8.02 | 40.1K | 1,564,000 | — | ↗ |
| 2022-07-21 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 833 | 8.08 | 6.7K | 100,000 | — | ↗ |
| 2022-07-20 | Opaleye Management Inc. | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 4,500 | 8.08 | 36.3K | 1,549,500 | — | ↗ |
| 2022-07-14 | EW HEALTHCARE PARTNERS FUND 2, L.P. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 8.01 | 40.1K | 3,610,709 | — | ↗ |
| 2022-07-11 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 8.03 | 40.2K | 3,605,709 | — | ↗ |
| 2022-07-06 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 8.07 | 40.4K | 3,585,709 | — | ↗ |
| 2022-06-30 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 7.52 | 37.6K | 3,575,709 | — | ↗ |
| 2022-06-27 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 7.22 | 36.1K | 3,550,709 | — | ↗ |
| 2022-06-24 | Opaleye Management Inc. | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 2,000 | 6.99 | 14.0K | 1,542,000 | — | ↗ |
| 2022-06-22 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 2,000 | 6.99 | 14.0K | 1,542,000 | — | ↗ |
| 2022-06-22 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 6.47 | 32.4K | 3,535,709 | — | ↗ |
| 2022-06-16 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 6.25 | 31.3K | 3,530,709 | — | ↗ |
| 2022-06-13 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 5.90 | 29.5K | 3,515,709 | — | ↗ |
| 2022-06-10 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 25,000 | 5.60 | 140.1K | 1,490,000 | — | ↗ |
| 2022-06-08 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 5.80 | 29.0K | 3,500,709 | — | ↗ |
| 2022-06-07 | Cuca Roberto | Officer | P-Purchase | A | Common Stock | 15,000 | 5.50 | 82.5K | 34,892 | — | ↗ |
| 2022-06-03 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 5.99 | 30.0K | 3,480,709 | — | ↗ |
| 2022-06-02 | Quaker BioVentures II LP | 10% Owner | J-Other | D | Common Stock | 1,751,100 | 0.00 | — | 0 | — | ↗ |
| 2022-06-02 | Quaker BioVentures Capital II, L.P. | Director | J-Other | D | Common Stock | 1,751,100 | 0.00 | — | 0 | — | ↗ |
| 2022-06-01 | O'Brien Federica F. | Director | A-Award | A | Common Stock | 3,135 | 0.00 | — | 3,135 | — | ↗ |
| 2022-06-01 | Nosenzo John | Director | A-Award | A | Stock Option (Right to Buy) | 5,360 | 0.00 | — | 5,360 | — | ↗ |
| 2022-06-01 | EVANS DOUGLAS G | Director | A-Award | A | Common Stock | 3,135 | 0.00 | — | 3,135 | — | ↗ |
| 2022-06-01 | COLLERAN LISA N | Director | A-Award | A | Stock Option (Right to Buy) | 5,360 | 0.00 | — | 5,360 | — | ↗ |
| 2022-06-01 | Burgess Vincent J | Director | A-Award | A | Stock Option (Right to Buy) | 5,360 | 0.00 | — | 5,360 | — | ↗ |
| 2022-06-01 | Azarbarzin Kurt | Director | A-Award | A | Common Stock | 3,135 | 0.00 | — | 3,135 | — | ↗ |
| 2022-05-31 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 6.99 | 35.0K | 3,470,709 | — | ↗ |
| 2022-05-25 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 7.43 | 37.2K | 3,455,709 | — | ↗ |
| 2022-05-20 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 8.79 | 44.0K | 3,430,709 | — | ↗ |
| 2022-05-17 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 8.96 | 44.8K | 3,420,709 | — | ↗ |
| 2022-05-12 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 8.61 | 43.1K | 3,410,709 | — | ↗ |
| 2022-05-09 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 8.82 | 44.1K | 3,395,709 | — | ↗ |
| 2022-05-05 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 9.55 | 47.8K | 3,380,709 | — | ↗ |
| 2022-05-02 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 9.53 | 47.7K | 3,370,709 | — | ↗ |
| 2022-04-27 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 9.09 | 45.5K | 3,350,709 | — | ↗ |
| 2022-04-25 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 10,000 | 9.24 | 92.4K | 3,340,709 | — | ↗ |
| 2022-04-14 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 9.80 | 49.0K | 3,322,509 | — | ↗ |
| 2022-03-31 | Talmo Paul | Officer | F-InKind | D | Common Stock | 185 | 11.63 | 2.2K | 41,462 | — | ↗ |
| 2022-03-31 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 93 | 11.63 | 1.1K | 12,089 | — | ↗ |
| 2022-03-31 | Murphy Peter C. | Officer | F-InKind | D | Common Stock | 163 | 11.63 | 1.9K | 23,196 | — | ↗ |
| 2022-03-31 | KOBLISH ANTONY | Officer | F-InKind | D | Common Stock | 384 | 11.63 | 4.5K | 237,853 | — | ↗ |
| 2022-03-31 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 684 | 11.45 | 7.8K | 3,316,920 | — | ↗ |
| 2022-03-29 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 2,645 | 11.65 | 30.8K | 3,311,236 | — | ↗ |
| 2022-03-22 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 136 | 11.65 | 1.6K | 3,305,539 | — | ↗ |
| 2022-03-16 | EW Healthcare Partners Fund 2-UGP, LLC | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 3,473 | 11.68 | 40.6K | 3,302,972 | — | ↗ |
| 2022-02-24 | Talmo Paul | Officer | F-InKind | D | Common Stock | 1,023 | 11.98 | 12.3K | 41,647 | — | ↗ |
| 2022-02-24 | Smeykal Megan | Officer | F-InKind | D | Common Stock | 535 | 11.98 | 6.4K | 12,182 | — | ↗ |
| 2022-02-24 | Murphy Peter C. | Officer | F-InKind | D | Common Stock | 939 | 11.98 | 11.2K | 23,359 | — | ↗ |
| 2022-02-24 | KOBLISH ANTONY | Director / Officer | A-Award | A | Common Stock | 46,500 | 0.00 | — | 240,924 | — | ↗ |
| 2022-02-24 | Greenhalgh Ellis Skott | Officer | F-InKind | D | Common Stock | 973 | 11.98 | 11.7K | 27,826 | — | ↗ |
| 2022-02-24 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 5,572 | 11.74 | 65.4K | 3,299,499 | — | ↗ |
| 2022-02-23 | Talmo Paul | Officer | A-Award | A | Common Stock | 12,200 | 0.00 | — | 42,670 | — | ↗ |
| 2022-02-23 | Smeykal Megan | Officer | A-Award | A | Common Stock | 5,000 | 0.00 | — | 12,717 | — | ↗ |
| 2022-02-23 | Murphy Peter C. | Officer | A-Award | A | Common Stock | 10,800 | 0.00 | — | 24,298 | — | ↗ |
| 2022-02-23 | Greenhalgh Ellis Skott | Officer | A-Award | A | Stock Option (Right to Buy) | 6,675 | 11.75 | 78.4K | 6,675 | — | ↗ |
| 2022-02-23 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 750,657 | 11.75 | 8.82M | 3,293,927 | — | ↗ |
| 2022-02-23 | Cuca Roberto | Officer | A-Award | A | Stock Option (Right to Buy) | 26,600 | 11.75 | 312.6K | 26,600 | — | ↗ |
| 2022-02-22 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 3,579 | 11.74 | 42.0K | 2,543,270 | — | ↗ |
| 2022-02-18 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 2,520 | 11.75 | 29.6K | 2,539,691 | — | ↗ |
| 2022-02-17 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 6,810 | 11.73 | 79.9K | 2,537,171 | — | ↗ |
| 2022-02-16 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 10,000 | 11.72 | 117.2K | 2,530,361 | — | ↗ |
| 2022-02-15 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 29 | 11.75 | 340.75 | 2,520,361 | — | ↗ |
| 2022-02-14 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 10 | 11.75 | 117.50 | 2,520,332 | — | ↗ |
| 2022-02-11 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 7,082 | 11.74 | 83.1K | 2,520,322 | — | ↗ |
| 2022-02-10 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 520 | 11.75 | 6.1K | 2,513,240 | — | ↗ |
| 2022-02-09 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 1,327 | 11.75 | 15.6K | 2,512,720 | — | ↗ |
| 2022-02-08 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 500 | 11.75 | 5.9K | 2,511,393 | — | ↗ |
| 2022-01-31 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 1,950 | 11.74 | 22.9K | 2,510,893 | — | ↗ |
| 2022-01-28 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 11.33 | 56.7K | 2,508,943 | — | ↗ |
| 2022-01-27 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 11.51 | 57.6K | 2,503,943 | — | ↗ |
| 2022-01-26 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 4,993 | 11.74 | 58.6K | 2,498,943 | — | ↗ |
| 2022-01-25 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 3,846 | 11.92 | 45.8K | 2,493,950 | — | ↗ |
| 2022-01-24 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 11.68 | 58.4K | 2,490,104 | — | ↗ |
| 2022-01-14 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 567,467 | 12.00 | 6.81M | 2,485,104 | — | ↗ |
| 2022-01-12 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 12.50 | 62.5K | 1,917,637 | — | ↗ |
| 2022-01-11 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 5,000 | 12.38 | 61.9K | 1,912,637 | — | ↗ |
| 2022-01-10 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 1,409 | 12.46 | 17.6K | 1,907,637 | — | ↗ |
| 2022-01-01 | Talmo Paul | Officer | — | D | Common Stock | 0 | 0.00 | — | 30,470 | — | ↗ |
| 2022-01-01 | Smeykal Megan | Officer | — | D | Common Stock | 0 | 0.00 | — | 7,717 | — | ↗ |
| 2021-12-31 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 5,928 | 12.46 | 73.9K | 1,906,228 | — | ↗ |
| 2021-12-20 | EW HEALTHCARE PARTNERS FUND 2, L.P. | — | P-Purchase | A | Common Stock, par value $0.001 per share | 4,300 | 12.22 | 52.5K | 1,900,300 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-155.6K
Shares Outstanding
44.74M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2019 | Antony Koblish President and Chief Executive Officer | 402.5K | — | — | 1.84M | 157.0K | — | 2.40M | 76.68% | ↗ |
| 2 | 2019 | Maarten Persenaire Chief Medical Officer | 293.8K | — | — | 499.2K | 114.6K | — | 907.7K | 55.00% | ↗ |
| 3 | 2019 | E. Skott Greenhalgh Chief Technology Officer | 289.7K | — | — | 442.2K | 113.0K | — | 844.9K | 52.33% | ↗ |
| 4 | 2018 | Antony Koblish President and Chief Executive Officer | 375.0K | — | — | 29.8K | 164.1K | — | 568.9K | 5.25% | ↗ |
| 5 | 2018 | Maarten Persenaire Chief Medical Officer | 280.0K | — | — | 7.5K | 122.5K | — | 410.0K | 1.83% | ↗ |
| 6 | 2018 | E. Skott Greenhalgh Chief Technology Officer | 275.0K | — | — | 7.6K | 120.3K | — | 403.0K | 1.90% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Antony Koblish | Co-founder, Chief Executive Officer & Director | 1M | male |
| Roberto E. Cuca | CFO, Corporate Secretary & COO | 668.4K | male |
| Paul Talmo | Chief Technology Officer | 580.6K | male |
| Jeffrey Blizard | President | 16.3K | male |
| Jim Hagen | Senior VP of Strategic Commercial Operations & Marketing | — | male |
| Louisa Smith | Investor Relations Contact Officer | — | — |
| Megan Smeykal | Vice President, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer | — | female |
| Michael Leonard | Senior Vice President of Technical Operations | — | male |
| Gregory A. Firestone | Chief Business Officer | — | male |
| D. Taylor Ocasio | General Counsel & Corporate Secretary | — | male |
| Jennifer Lou Armstrong | Senior Vice President of Human Resources | — | female |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TELA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
